Acadia Pharma (NASDAQ: ACAD) announced that the New Drug Application (NDA) for NUPLAZID™ (pimavanserin) has been accepted for review ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE